Opiant Pharmaceuticals Announces First Quarter 2021 Financial Results and Corporate Update

SANTA MONICA, Calif., May 11, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended March 31, 2021, and provided a corporate update. Recent highlights include: Pipeline and Corporate Update OPNT003, nasal nalmefene, for opioid overdose: Confirmatory pharmacokinetic (“PK”) study close to completing enrollment and on track to report data in early Q3First subjects dosed in head-to-head clinical pharmacodynamic (“PD”) study comparing the effectiveness of OPNT003, nasal nalmefene, with nasal naloxone; data anticipated in the fourth quarter Other drug development activities necessary for NDA filing on track to deliver data by year-end The Center for Disease Control released provisional data for the year ending September 2020: 66,813 overdose were caused by opioids (predicted)80% or 53,877 opioid overse deaths (predicted) were linked to illicit synthetic opioids, and particularly fentanyl Awarded third and final tranche of $1.8 million from the total grant of approximately $7.4 million from the National Institute on Drug Abuse (“NIDA”), part of the National Institutes of Health, to support the development of OPNT003 OPNT004, drinabant, for Acute Cannabinoid Overdose:  Preclinical activities and formulation development on track to support an IND for parenteral administration OPNT002, nasal naltrexone, for Alcohol Use Disorder: Start of Phase 2 study, which was paused due to the ongoing COVID-19 pandemic, remains on pause; Company is assessing optimal time to proceed Strengthened board of directors with the addition of seasoned clinical development executive, Lorianne Masuoka, M.D., in March 2021 Financial Highlights Q1 revenues of $6.4 million driven by royalties from the sale of NARCAN® Nasal Spray (“NARCAN®”) As of March 31, 2021, $50.6 million in cash, cash equivalents, and marketable securities  Commenting, Roger Crystal, M.D., President and Chief Executive Officer of Opiant, said: “Opiant had a strong start to 2021, including the commencement of our confirmatory PK and PD studies for OPNT003, nasal nalmefene, for opioid overdose. Our comprehensive development of OPNT003 is indicative of our firm commitment to delivering new medicines to save lives from addictions and drug overdose and support public health in the face of a worsening drug overdose crisis driven primarily by opioids. We believe OPNT003 may be particularly effective for the treatment of overdoses from synthetic opioids, like fentanyl, which is the leading cause of drug overdose death in America.”  David O’Toole, Chief Financial Officer of Opiant, said: “We remain in a strong financial position to support our ongoing drug development activities and clinical studies, as well as to ramp up pre-commercial efforts for our lead program, OPNT003.” First quarter 2021 resultsFor the three months ended March 31, 2021, Opiant recorded approximately $6.4 million in revenue, compared to approximately $4.3 million during the corresponding period of 2020. For the three months ended March 31, 2021, we recorded approximately $4.3 million of revenue from our license agreement with Emergent BioSolutions, Inc. (“EBS”) for the sale of NARCAN®, compared to approximately $4.2 million in the same period of 2020. First quarter 2021 sales of NARCAN® were approximately $74.2 million, as reported by EBS. For the three months ended March 31, 2021, general and administrative expenses were approximately $2.6 million, the same as the comparable period of 2020. Research and development expenses for the three months ended March 31, 2021, were approximately $4.1 million, as compared to approximately $1.4 million in the comparable period in 2020. External development expense increased by $2.6 million due to increased activity on our lead product candidate, OPNT003 – Nasal Nalmefene. In addition, personnel and related expense increased by approximately $0.1 million during the three months ended March 31, 2021 compared to the three months ended March 31, 2020. Sales and marketing expenses for the three months ended March 31, 2021, were approximately $1.0 million for pre-commercialization efforts related to OPNT003, nasal nalmefene. Sales and marketing expense during the three months ended March 31, 2020 was approximately $1.1 million. Royalty expense for the three months ended March 31, 2021, was approximately $1 million, compared to $0.9 million for the comparable period of 2020. Net loss for the three months ended March 31, 2021, was approximately $2.8 million, or a loss of $0.66 per basic and diluted share, compared to net loss of approximately $1.7 million, or a loss of $0.40 per basic and diluted share, for the comparable period of 2020. As of March 31, 2021, Opiant had $50.6 million in cash, cash equivalents, and marketable securities. Current cash balance does not include the full impact of the NIDA grant of approximately $7.4 million or the Biomedical Advanced Research and Development Authority contract of approximately $8.1 million. Based on the mid-range of the full-year 2021 guidance for sales of NARCAN® Nasal Spray provided by EBS, of $315 million, we continue to expect full-year 2021 royalty revenue from the sale of NARCAN® Nasal Spray of approximately $27.8 million. We also expect to end 2021 with cash and cash equivalents of approximately $40 million, which will not include any receipt of additional tranches of the convertible debt deal. Conference Call Details: Tuesday, May 11th at 4:30 p.m. Eastern Time/1:30 p.m. Pacific TimeToll Free:877-407-0792International:201-689-8263Conference ID:13718590Webcast:http://ir.opiant.com/ About Opiant Pharmaceuticals, Inc.Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.For more information visit: www.opiant.com. Forward-Looking StatementsThis press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, and among other things, our ability to maintain cash balances and successfully commercialize or partner our product candidates currently under development. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other same terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. Additional factors that could materially affect actual results can be found in our filed quarterly reports on Form 10-Q and our annual report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 4, 2021, including under the caption titled “Risk Factors.”  These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.Investor Relations Contacts: Ben AtkinsVP of Corporate Communications and Investor [email protected](310) 598-5410 Opiant Pharmaceuticals, Inc.Condensed Consolidated Balance Sheets(in thousands, except shares and per share amounts)           As of March 31, As of December 31,     2021   2020 Assets (unaudited)   Current assets      Cash & cash Equivalents $35,450  $48,251   Marketable securities  12,598   –   Accounts receivable  5,609   8,911   Prepaid expenses and other current assets  2,447   1,937       Total current assets  56,104   59,099  Other assets      Marketable securities  2,501   –   Property and equipment, net  140   171   Right of use assets – operating leases  146   279   Patents and patent applications, net  12   13   Other non-current assets  –   1,051       Total assets $58,903  $60,613        Liabilities and stockholders’ equity     Current liabilities      Accounts payable and accrued liabilities $3,680  $2,966   Accrued salaries and wages  481   909   Royalty payable  980   1,908   Deferred revenue  859   355   Operating leases  149   282       Total current liabilities  6,149   6,420  Long-term liabilities      Convertible debt, net of unamortized discount  18,769   18,701       Total long-term liabilities  18,769   18,701       Total liabilities  24,918   25,121  Stockholders’ equity     Common stock, $0.001 par value, 200,000,000 shares authorized, 4,330,594 and 4,258,105 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively  4   4  Additional paid-in-capital  101,529   100,204  Accumulated other comprehensive loss  (15)  (27) Accumulated deficit  (67,533)  (64,689)  Total stockholders’ equity  33,985   35,492       Total liabilities and stockholders’ equity $58,903  $60,613         Opiant Pharmaceuticals Inc. Condensed Consolidated Statements of Operations(in thousands, except shares and per share amounts)             Three months ended Three months ended     March 31, March 31,      2021   2020      (Unaudited) (Unaudited)Revenues      Royalty revenue  $4,334  $4,199  Grant and contract revenue   2,053   84   Total Revenue   6,387   4,283 Operating expenses      General and administrative   2,646   2,573  Research and development   4,088   1,421  Sales & marketing   998   1,077  Royalty expense   980   934           Total expenses   8,712   6,005           Loss from operations   (2,325)  (1,722)        Other income (expense)      Interest income   3   76  Interest expense   (537)  –  Loss on foreign exchange   14   –   Total other income (expense)   (520)  76 Loss before provision for income taxes   (2,845)  (1,646)Income tax expense   –   39 Net loss  $(2,845) $(1,685)        Other comprehensive loss:      Foreign currency translation adjustment   13   (293)Comprehensive loss  $(2,832) $(1,978)        Net loss per common share      Basic & Diluted  $(0.66) $(0.40)        Weighted-average common shares outstanding:     Basic & Diluted   4,282,923   4,224,555